This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
BioMarin Pharmaceutical Balans Gezondheid
Financiële gezondheid criteriumcontroles 5/6
BioMarin Pharmaceutical has a total shareholder equity of $4.9B and total debt of $1.1B, which brings its debt-to-equity ratio to 22.2%. Its total assets and total liabilities are $6.8B and $1.9B respectively. BioMarin Pharmaceutical's EBIT is $120.0M making its interest coverage ratio -3.5. It has cash and short-term investments of $1.1B.
Belangrijke informatie
22.2%
Verhouding schuld/eigen vermogen
US$1.09b
Schuld
| Rente dekkingsratio | -3.5x |
| Contant | US$1.13b |
| Aandelen | US$4.90b |
| Totaal verplichtingen | US$1.86b |
| Totaal activa | US$6.76b |
Recente financiële gezondheidsupdates
Geen updates
Recent updates
Analyse van de financiële positie
Kortlopende schulden: BM8's short term assets ($3.0B) exceed its short term liabilities ($1.2B).
Langlopende schulden: BM8's short term assets ($3.0B) exceed its long term liabilities ($698.0M).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: BM8 has more cash than its total debt.
Schuld verminderen: BM8's debt to equity ratio has reduced from 41.2% to 22.2% over the past 5 years.
Schuldendekking: BM8's debt is not well covered by operating cash flow (12.8%).
Rentedekking: BM8 earns more interest than it pays, so coverage of interest payments is not a concern.